CN117244002A - Veterinary preparation for treating diarrhea - Google Patents
Veterinary preparation for treating diarrhea Download PDFInfo
- Publication number
- CN117244002A CN117244002A CN202311267475.2A CN202311267475A CN117244002A CN 117244002 A CN117244002 A CN 117244002A CN 202311267475 A CN202311267475 A CN 202311267475A CN 117244002 A CN117244002 A CN 117244002A
- Authority
- CN
- China
- Prior art keywords
- diarrhea
- preparation
- veterinary
- treating
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012735 Diarrhoea Diseases 0.000 title claims abstract description 155
- 238000002360 preparation method Methods 0.000 title claims abstract description 98
- 239000003814 drug Substances 0.000 claims abstract description 83
- 241001465754 Metazoa Species 0.000 claims abstract description 49
- 229940079593 drug Drugs 0.000 claims abstract description 38
- 244000307545 Elaeagnus angustifolia Species 0.000 claims abstract description 29
- 235000017643 Elaeagnus angustifolia Nutrition 0.000 claims abstract description 29
- 241000784794 Halostachys Species 0.000 claims abstract description 29
- 241000123887 Pulsatilla chinensis Species 0.000 claims abstract description 28
- 235000001456 Elaeagnus latifolia Nutrition 0.000 claims abstract description 20
- 235000007630 Elaeagnus umbellata var parvifolia Nutrition 0.000 claims abstract description 20
- 239000000287 crude extract Substances 0.000 claims abstract description 13
- 239000007788 liquid Substances 0.000 claims description 69
- 150000001875 compounds Chemical class 0.000 claims description 61
- 150000003839 salts Chemical class 0.000 claims description 38
- 239000002023 wood Substances 0.000 claims description 37
- 239000000284 extract Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 15
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 14
- 238000009472 formulation Methods 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 235000019687 Lamb Nutrition 0.000 claims description 12
- 244000309466 calf Species 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 8
- 239000007927 intramuscular injection Substances 0.000 claims description 7
- 238000010255 intramuscular injection Methods 0.000 claims description 7
- 239000007928 intraperitoneal injection Substances 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000009806 pulsatillae Substances 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000000967 suction filtration Methods 0.000 claims description 3
- 238000009210 therapy by ultrasound Methods 0.000 claims description 3
- 229940126680 traditional chinese medicines Drugs 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 42
- 230000000694 effects Effects 0.000 abstract description 32
- 241000588724 Escherichia coli Species 0.000 abstract description 19
- 241000894006 Bacteria Species 0.000 abstract description 11
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 6
- 244000063299 Bacillus subtilis Species 0.000 abstract description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 235000014722 Aralia cordata Nutrition 0.000 abstract description 3
- 235000004446 Aralia racemosa Nutrition 0.000 abstract description 3
- 235000010658 Lavandula latifolia Nutrition 0.000 abstract description 3
- 239000008280 blood Substances 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 abstract description 3
- 238000001816 cooling Methods 0.000 abstract description 3
- 210000000952 spleen Anatomy 0.000 abstract description 3
- 238000005728 strengthening Methods 0.000 abstract description 3
- 244000294554 Aralia racemosa Species 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 51
- 238000012360 testing method Methods 0.000 description 45
- 241000699670 Mus sp. Species 0.000 description 27
- 241000283903 Ovis aries Species 0.000 description 19
- 208000024891 symptom Diseases 0.000 description 13
- 241000411851 herbal medicine Species 0.000 description 12
- 239000003242 anti bacterial agent Substances 0.000 description 11
- 230000003115 biocidal effect Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 230000034994 death Effects 0.000 description 9
- 231100000517 death Toxicity 0.000 description 9
- 229930182566 Gentamicin Natural products 0.000 description 8
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 8
- 229940088710 antibiotic agent Drugs 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 229960002518 gentamicin Drugs 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- -1 compound salt Chemical class 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 5
- 238000009395 breeding Methods 0.000 description 5
- 230000001488 breeding effect Effects 0.000 description 5
- 230000000857 drug effect Effects 0.000 description 5
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 244000144972 livestock Species 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 2
- 208000031295 Animal disease Diseases 0.000 description 2
- 241000722818 Aralia Species 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 239000012880 LB liquid culture medium Substances 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- RDEIXVOBVLKYNT-HDZPSJEVSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-[(1r)-1-aminoethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2 Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)[C@@H](C)N)N)[C@@H](N)C[C@H]1N.O1[C@H]([C@@H](C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-HDZPSJEVSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000223935 Cryptosporidium Species 0.000 description 1
- NOQGZXFMHARMLW-UHFFFAOYSA-N Daminozide Chemical compound CN(C)NC(=O)CCC(O)=O NOQGZXFMHARMLW-UHFFFAOYSA-N 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010051511 Viral diarrhoea Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000002815 broth microdilution Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000035611 feeding Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a veterinary preparation for treating diarrhea; belongs to the technical field of medicines: (1) The crude extract of the halostachys sieboldii has antibacterial effect on escherichia coli, staphylococcus aureus and bacillus subtilis; (2) The pulsatilla chinensis has the effects of clearing heat and detoxicating, cooling blood and stopping diarrhea, and the fructus oleaster has the effects of tonifying qi and strengthening spleen, astringing and stopping diarrhea, and the fructus oleaster are used as auxiliary medicines, so that the effect of rapidly treating diarrhea is achieved; (3) The three medicines of the spikenard, the pulsatilla chinensis and the elaeagnus angustifolia are combined to play roles of inhibiting bacteria and relieving diarrhea, clearing heat and detoxicating and relieving diarrhea and astringing and stopping diarrhea for diarrhea animals, so that the effect of all-round diarrhea is achieved.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a veterinary preparation for treating diarrhea.
Background
The salt spike wood is used as the dominant desert vegetation growing in Xinjiang desert and saline-alkali soil zone, is a plant for improving the ecological system of the saline-alkali soil, has good ecological value and significance, and researches show that the salt spike wood not only has good nutritional value, but also has good antibacterial effect on stem and leaf extracts of the salt spike wood, and has inhibition effect on escherichia coli, staphylococcus aureus and bacillus subtilis, wherein the antibacterial effect on staphylococcus aureus is the best.
For many years, due to the fact that antibiotics are used in a large amount in livestock breeding industry, more drug-resistant bacteria appear in the production of the livestock breeding industry, so that the phenomena of poor or ineffective drug effect and the like often appear in animal disease prevention and treatment, the method is one of the current solutions for relieving the problem caused by antibiotics in animal diseases by replacing the prevention and treatment of the antibiotics with Chinese herbal medicines due to the fact that the drug-resistant bacteria and food safety and the like are relieved caused by the large amount of antibiotics in the breeding industry, and the method is found in the early-stage study of the salt spike wood, has good nutritional value and good antibacterial effect on part of bacteria, and can be used for further excavating and developing the medicinal value of the salt spike wood, so that the method can effectively utilize plant resources of desertification lands and the like, and can provide a new solution for the problem of abuse of the antibiotics.
In the animal breeding process, animal diarrhea caused by pathogenic microorganisms is common, the existing multi-purpose antibiotics for treating animal diarrhea are used for treating, pathogenic microorganisms are easy to generate drug resistance and have poor treatment effect, in the existing process of ensuring animal food safety, many farms advocate no-resistance breeding, after the animals are ill, chinese herbal medicines, probiotics and the like are mainly used for treating, and effective and convenient Chinese herbal preparations are not a lot of short plates of veterinary Chinese herbal preparations at present, so that development and application of Chinese herbal medicines are imperative for diarrhea prevention and treatment.
The Chinese herbal medicine has rich Chinese herbal medicine type resources, the Chinese herbal medicine preparation has the characteristics of no pollution, no drug resistance, no residue and the like, and has the functions of resisting bacteria, regulating immunity and the like, in order to reduce the loss of diarrhea caused by pathogenic bacteria to the breeding industry, the Chinese herbal medicine is used as a main component to prepare the Chinese herbal medicine preparation and the Chinese herbal medicine product, which are one of methods for preventing and treating animal diarrhea, and the research result of the halostachys sieboldii proves that the halostachys sieboldii extract has a better antibacterial effect on staphylococcus aureus and a certain antibacterial effect on escherichia coli; in livestock production, animal diarrhea caused by escherichia coli is common, but due to abuse of antibiotics, the diarrhea caused by escherichia coli is difficult to prevent and treat, and the antibacterial activity of the crude extract of the halostachys sieboldii has higher stability, so that the halostachys sieboldii compound preparation for treating diarrhea of animals has higher clinical medicinal value.
Disclosure of Invention
Aiming at the situation, in order to overcome the defects of the prior art, the invention provides a veterinary preparation for treating diarrhea, and the crude extract of the halostachys sieboldii has antibacterial effect on escherichia coli, staphylococcus aureus and bacillus subtilis; the pulsatilla chinensis has the effects of clearing heat and detoxicating, cooling blood and stopping diarrhea, and the fructus oleaster has the effects of tonifying qi and strengthening spleen, astringing and stopping diarrhea, and the fructus oleaster are used as auxiliary medicines, so that the effect of rapidly treating diarrhea is achieved; the three medicines of the spikenard, the pulsatilla chinensis and the elaeagnus angustifolia are combined to play roles of inhibiting bacteria and relieving diarrhea, clearing heat and detoxicating and relieving diarrhea and astringing and stopping diarrhea for diarrhea animals, so that the effect of all-round diarrhea is achieved.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows: the veterinary preparation for treating diarrhea is a tablet, and comprises the following components in percentage by weight: 40% of crude salt spike wood alcohol extract, 60% of pulsatilla chinensis and 60% of oleaster water extract.
Further, the veterinary preparation for treating diarrhea is a liquid preparation, and comprises the following components in percentage by weight: 40% of salt spike wood, 30% of oleaster and 30% of pulsatilla chinensis.
The invention also provides a preparation method of the veterinary preparation for treating diarrhea, which comprises the following steps:
(1) Preparing a crude extract of the spica gracilis: 200g of salt spike wood stem leaves are weighed, crushed, added into 1000mL of 85% ethanol solution, soaked for 12-24h, subjected to ultrasonic treatment for 30min, then subjected to suction filtration, finally subjected to vacuum concentration by using a rotary evaporator, repeatedly soaked and suction filtered for three times by each sample, and the salt spike wood soaked solutions recovered for 3 times under reduced pressure are combined and concentrated into 1g/mL of medicine concentration liquid, and stored at 4 ℃ for standby;
(2) Preparing a water extract of pulsatilla chinensis and elaeagnus angustifolia: weighing 100g of pulsatilla chinensis and fructus oleaster respectively, crushing, wrapping with 3 layers of medical gauze respectively, adding distilled water respectively for soaking for 4 hours, adding distilled water 10, 8 and 6 times of the volume of the traditional Chinese medicines respectively for decoction, continuously decocting with slow fire for 1 hour after each decoction boiling, suction filtering and preserving, finally merging the 3 times of filtrate for concentration, and preserving at 4 ℃ for later use;
(3) Preparation of compound preparation (liquid agent): uniformly mixing the crude extract of the spica, the pulsatilla chinensis and the water extract of the oleaster prepared in the step (1) and the step (2) according to a proportion to form a veterinary salt spica compound preparation for treating animal diarrhea;
(4) Preparation of compound preparation (tablet): pulverizing Salicomia Herbacea, fructus Elaeagni Angustifoliae and radix Pulsatillae, mixing at a certain proportion, adding starch, mixing, and tabletting with tablet machine, wherein each tablet is 1g of crude drug.
Preferably, the soaking in the step (1) should be performed in a light-proof environment.
Preferably, the final crude drug concentration in the step (2) is 1g/mL.
Preferably, the concentration of the liquid medicine in the step (3) is 1g/mL.
Preferably, the ratio of the traditional Chinese medicine powder to the starch in the step (4) is 1:1.2.
Further, the halostachys sieboldii liquid for treating animal diarrhea can be applied to: mouse dosage: 0.4 mL/dose, orally taken, 1 time a day, and continuously taken for 3d; rabbit dosage: 1mL/kg, intraperitoneal injection, 1 time a day, continuous administration of 6d and piglet dosage: intramuscular injection, 2 mL/time, 2 times a day, was continued for 6d.
Further, the veterinary halostachys sieboldii tablet for treating animal diarrhea can be applied to: lamb consumption: 1.6g/kg, or 2 tablets at a time, orally taken 2-3 times a day, and continuously taken for 6d; calf dosage: 4 tablets each time are orally taken for 2-3 times a day, and the medicine is continuously taken for 6 days; the dosage of piglets is as follows: 2-4 tablets each time are orally taken, 2-3 times a day, and the medicine is continuously taken for 6 days.
The beneficial effects obtained by the invention by adopting the structure are as follows: (1) The crude extract of the halostachys sieboldii has antibacterial effect on escherichia coli, staphylococcus aureus and bacillus subtilis; (2) The pulsatilla chinensis has the effects of clearing heat and detoxicating, cooling blood and stopping diarrhea, and the fructus oleaster has the effects of tonifying qi and strengthening spleen, astringing and stopping diarrhea, and the fructus oleaster are used as auxiliary medicines, so that the effect of rapidly treating diarrhea is achieved; (3) The three medicines of the spikenard, the pulsatilla chinensis and the elaeagnus angustifolia are combined to play roles of inhibiting bacteria and relieving diarrhea, clearing heat and detoxicating and relieving diarrhea and astringing and stopping diarrhea for diarrhea animals, so that the effect of all-round diarrhea is achieved.
Drawings
FIG. 1 winter photographs of salt ear wood;
FIG. 2 is a tablet diagram of the compound salt spike wood preparation;
FIG. 3 is a cecum bulge view of rabbits;
FIG. 4 shows ascites patterns in the abdomen of rabbits.
The accompanying drawings are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate the invention and together with the embodiments of the invention, serve to explain the invention.
Detailed Description
The following description of the embodiments of the present invention will be made clearly and fully with reference to the accompanying drawings, in which it is evident that the embodiments described are only some, but not all embodiments of the invention; all other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In addition, any methods and materials similar or equivalent to those described herein can be used in the present invention. The preferred methods and materials described herein are illustrative only and should not be construed as limiting the scope of the present application.
The experimental methods in the following examples are all conventional methods unless otherwise specified; the test materials and test strains used in the examples described below, unless otherwise specified, were commercially available.
The invention provides a veterinary preparation for treating diarrhea
The veterinary preparation for treating diarrhea is a tablet, and comprises the following components in percentage by weight: 40% of crude salt spike wood alcohol extract, 60% of pulsatilla chinensis and 60% of oleaster water extract.
Further, the veterinary preparation for treating diarrhea is a liquid preparation, and comprises the following components in percentage by weight: 40% of salt spike wood, 30% of oleaster and 30% of pulsatilla chinensis.
The invention also provides a preparation method of the veterinary preparation for treating diarrhea, which comprises the following steps:
(1) Preparing a crude extract of the spica gracilis: 200g of salt spike wood stem leaves are weighed, crushed, added into 1000mL of 85% ethanol solution, soaked for 12-24h, subjected to ultrasonic treatment for 30min, then subjected to suction filtration, finally subjected to vacuum concentration by using a rotary evaporator, repeatedly soaked and suction filtered for three times by each sample, and the salt spike wood soaked solutions recovered for 3 times under reduced pressure are combined and concentrated into 1g/mL of medicine concentration liquid, and stored at 4 ℃ for standby;
(2) Preparing a water extract of pulsatilla chinensis and elaeagnus angustifolia: weighing 100g of pulsatilla chinensis and fructus oleaster respectively, crushing, wrapping with 3 layers of medical gauze respectively, adding distilled water respectively for soaking for 4 hours, adding distilled water 10, 8 and 6 times of the volume of the traditional Chinese medicines respectively for decoction, continuously decocting with slow fire for 1 hour after each decoction boiling, suction filtering and preserving, finally merging the 3 times of filtrate for concentration, and preserving at 4 ℃ for later use;
(3) Preparation of compound preparation (liquid agent): uniformly mixing the crude extract of the spica, the pulsatilla chinensis and the water extract of the oleaster prepared in the step (1) and the step (2) according to a proportion to form a veterinary salt spica compound preparation for treating animal diarrhea;
(4) Preparation of compound preparation (tablet): pulverizing Salicomia Herbacea, fructus Elaeagni Angustifoliae and radix Pulsatillae, mixing at a certain proportion, adding starch, mixing, and tabletting with tablet machine, wherein each tablet is 1g of crude drug.
Preferably, the soaking in the step (1) should be performed in a light-proof environment.
Preferably, the final crude drug concentration in the step (2) is 1g/mL.
Preferably, the concentration of the liquid medicine in the step (3) is 1g/mL.
Preferably, the ratio of the traditional Chinese medicine powder to the starch in the step (4) is 1:1.2.
Further, the halostachys sieboldii liquid for treating animal diarrhea can be applied to: mouse dosage: 0.4 mL/dose, orally taken, 1 time a day, and continuously taken for 3d; rabbit dosage: 1mL/kg, intraperitoneal injection, 1 time a day, continuous administration of 6d and piglet dosage: intramuscular injection, 2 mL/time, 2 times a day, was continued for 6d.
Further, the veterinary halostachys sieboldii tablet for treating animal diarrhea can be applied to: lamb consumption: 1.6g/kg, or 2 tablets at a time, orally taken 2-3 times a day, and continuously taken for 6d; calf dosage: 4 tablets each time are orally taken for 2-3 times a day, and the medicine is continuously taken for 6 days; the dosage of piglets is as follows: 2-4 tablets each time are orally taken, 2-3 times a day, and the medicine is continuously taken for 6 days.
Example 1
Screening compound liquid medicine with better drug effect by external bacteriostasis test of halostachys sieboldii and compound crude extract liquid
The method comprises the steps of (1) performing in-vitro bacteriostasis test on single herbal medicine, determining the minimum bacteriostasis concentration (MIC) and the Minimum Bacteriostasis Concentration (MBC) by using a broth dilution method, adding prepared test bacterial liquid into a test tube, performing double dilution as shown in table 1, performing constant temperature culture on the test tube broth by adopting an MH broth culture medium, performing repeated three times of test on each bacterial and medicine, performing verification by adopting a culture liquid coating culture medium method on the test tube after culture, sucking 20uL of culture liquid by each culture tube, coating the culture liquid on a MAIKAI agar culture medium, performing constant temperature culture at 37 ℃ for 12-16 hours, and obtaining a test tube with no bacterial growth on the culture medium, namely MIC (-) of the medicine, wherein the test tube with the number of bacterial colonies which are coated and grown in the culture medium is less than 5, namely MBC (. + -.); colony count growth >5, using "+" to indicate light antibacterial effect; the coated bacteria grow vigorously and have no obvious colony, the "++" is used for indicating no antibacterial effect, and the average value of three repeated tests of each bacteria and herbal medicines is taken as test data to judge the antibacterial effect of the herbal medicines in vitro.
Table 1 shows diluted liquid medicine
Table 2 determination of inhibitory concentration
According to the growth condition of the cultured test tube broth on a MAIKAI culture medium, analyzing the influence results of each drug on the growth of different strains under different concentrations, and performing drug effect evaluation as compound crude extracts of the halostachys sieboldii, the pulsatilla chinensis, the elaeagnus angustifolia and the components thereof, and screening out compound liquid medicine with better drug effect, wherein the test result shows that the antibacterial effect on E.coli is in light antibacterial effect when the crude drug of the halostachys sieboldii extract is in the concentration of 500mg/mL, and does not meet the evaluation requirements of MIC and MBC; when the concentration of the pulsatilla chinensis water extract is higher than 250mg/mL, the pulsatilla chinensis water extract has a slight antibacterial effect on E.coli, but the concentration of the pulsatilla chinensis water extract still does not meet the judging requirements of MIC and MBC when reaching 500 mg/mL; when the concentration of the crude drug is 500mg/mL, the water extract of the elaeagnus angustifolia has a slight antibacterial effect on E.coli, but the evaluation requirements of MlC and MBC are not met, and the antibacterial potency of each drug among different strains is not different.
Experimental example 2
In-vitro antibacterial effect test of halostachys sieboldii compound, and determination of compound medicine component proportion
Three extracted herbs were used: mixing the crude salt spike wood alcohol extract (A solution), the pulsatilla chinensis and the water crude elaeagnus angustifolia extract liquid medicine (B solution) according to different proportions to respectively form a compound I (the A solution accounts for 40 percent), a compound II (the A solution accounts for 50 percent) and a compound III (the A solution accounts for 60 percent), detecting in vitro antibacterial effects of 3 pairs of compound liquid medicines, wherein the tested strains are an escherichia coli standard strain (ATCC 25922) and an escherichia coli strong pathogenic strain (G10) which are identified by separation, repeating each group of tests for three times, taking an average value to judge the antibacterial effects of the compound, and further evaluating the influence of different concentrations of the salt spike wood in the compound on E.coli antibacterial effects, and screening out the salt spike wood compound with the best antibacterial effects.
Table 3 antibacterial Compound Screen
Through result analysis, in the mixed solution (solution B) of the oleaster and the pulsatilla chinensis without adding the salt spike wood, when the concentration of crude drugs is 500mg/mL, the antibacterial effect is slightly sensitive, and other concentrations are all shown as no antibacterial effect, in the three drug compounds added with the salt spike wood, the antibacterial potency of compound I is highest, when the concentration of the crude drugs reaches 500mg/mL, MIC is generated but MBC is not generated, and when the concentration of the crude drugs is 250mg/mL, the antibacterial effect is slightly weakened; the antibacterial titers of compound II and compound III are not different in the test, MIC also appears when the concentration of crude drug is 500mg/mL, but the crude drug concentration is 250mg/mL, and the antibacterial titers of compound II and compound III are not obvious, although the antibacterial titers of compound II and compound III are worse than that of compound I, the antibacterial titers of compound II and compound III are higher than those of 'oleaster and pulsatilla chinensis mixed solution' (liquid B), and the antibacterial titers of various compound crude extracts among different strains are not obvious.
The in vitro antibacterial test result shows that in the screening test of the primary compound of the halostachys sieboldii, the compound No. I is the optimal antibacterial compound for the screening, so that the preparation method of the compound No. I is determined to be a standard method of a veterinary halostachys sieboldii compound preparation (liquid type) for treating animal diarrhea.
Experimental example 1
Detection of pharmacodynamic stability of veterinary preparation (liquid type) for treating diarrhea
The quality control strain and part of the isolate strain of ATCC25922 are used for detecting the drug effect stability of the compound preparation (liquid type) of the halostachys sieboldii for treating animal diarrhea: treating the extracted compound liquid medicine by autoclaving, and comparing in vitro bacteriostasis test to judge the influence of high temperature on the bacteriostasis effect of the medicine; the extracted compound liquid medicine is detected to have initial pH value (6.04 th. 0.5) by using pH test paper, then the other liquid medicine is regulated to neutral pH value (7.0 th. 0.5) by using sodium bicarbonate, and the two liquid medicines are compared by an in vitro antibacterial effect test, so that the influence of the pH value on the antibacterial effect of the medicine is judged.
Table 4 detection of pharmacodynamic stability of veterinary formulations (liquid form) for treating diarrhea
According to the result statistics, the in vitro antibacterial effect of the high-pressure and non-high-pressure animal salt spike wood compound preparation (liquid type) for treating the animal diarrhea disease is not different in an in vitro antibacterial test, and the antibacterial concentration of the animal salt spike wood compound preparation (liquid type) for treating the animal diarrhea disease is not obviously fluctuated in the test before and after the high pressure, so that the antibacterial components of the animal salt spike wood compound preparation (liquid type) for treating the animal diarrhea disease are relatively stable, and the antibacterial active components of the animal salt spike wood compound preparation (liquid type) for treating the animal diarrhea disease are not destroyed after the high-pressure treatment.
TABLE 5 influence of pH on antibacterial effect of salt spike Wood Compound preparation (liquid type)
The quality control bacteria of the escherichia coli ATCC25922 and pathogenic isolates G10 and G7 are used as experimental bacteria, and in an in-vitro bacteriostasis test of the salt spike wood compound preparation (liquid type) for treating the diarrhea of animals, the bacteriostasis effect of the salt spike wood compound preparation (liquid type) before and after treatment of the animal diarrhea is not different, so that the slight change of the pH value does not influence the bacteriostasis potency of the salt spike wood compound preparation (liquid type) for treating the diarrhea of animals.
Experimental example 2
Maximum tolerated dose test (MTD) of diarrhea veterinary formulation (liquid) mice
The mice are pathogenic: after rejuvenating the ATCC25922 quality control strain and part of the isolate for two generations, using LB liquid culture medium to carry out enrichment to prepare preliminary bacterial liquid required by infection, then using a Mitsubiuzole tube to prepare the preliminary bacterial liquid with the bacterial liquid concentration of 1.5X108 CFU/mL (namely, the Mitsubiuzole 0.5 tube), and carrying out intraperitoneal injection for each mouse at a dose of 0.2 mL/mouse.
Taking the prepared compound preparation (liquid type) of the halostachys sieboldii for treating animal diarrhea, wherein the concentration of the liquid medicine is 1g/mL, carrying out pre-experiments on the standard of the common dosage of 0.2-0.3mL/10g of infected mice, setting 6 groups of 4 mice, respectively carrying out semi-random distribution on male and female mice in each group, and setting drug concentration groups at low dosage (0.3 mL/one), medium dosage (0.4 mL/one) and high dosage (0.5 mL/one).
The control group 3 is filled with sterile normal saline, and the other 3 groups are filled with the compound preparation (liquid type) of the halostachys sieboldii for treating animal diarrhea. Mice were fasted for 12h without water control before the test, fed continuously for 3d 1 time a day, and observed for clinical symptoms and death within 7d after the administration.
Table 6 analysis experiments of therapeutic amounts of veterinary preparations (liquid) for diarrhea in mice
TABLE 7 maximum tolerability detection of diarrhea treating veterinary formulations (liquid type) on mice
After the pre-test is finished, the test result is analyzed to obtain a safer administration dosage range, the administration dosage safety test is carried out again in the range, the grouping and test method is the same as that of the pre-test, but the total number of mice in each group is increased to 10 mice/group, the clinical symptoms and death conditions of the mice in 7d are recorded after administration, and the death and the clinical symptoms (coma, mental excitement and the like) are serious when the maximum drug tolerance dose (MTD) is generated.
The analysis of the test results shows that the MTD of the animal halostachys sieboldii compound preparation for treating animal diarrhea is 0.45 mL/dose, and other dosage groups do not show abnormal clinical symptoms, so that the factors affecting the clinical treatment test are minimized, and in the clinical treatment test of mice, the treatment test is carried out by taking 0.4 mL/dose, orally taking for 1 time a day.
Experimental example 3
Drug treatment test of infected mice
Treatment experiments, 40 Kunming mice are selected, and randomly grouped into 4 groups of 10 mice each, and the male and female mice are half; the group A is a negative control group, does not use any medicine and does not carry out infection; group B is infection control group, and the infection method is the same; group C is antibiotic treatment group, gentamicin sulfate injection is used, the dosage of dogs and cats is 0.075-0.125mL/kg according to the drug instruction, and the dosage of dogs and cats is diluted 100 times, namely, the dosage of mice is 0.125mL/10g; the group D is a Chinese medicinal compound group I, and is treated by a Chinese medicinal compound preparation (liquid type) for treating animal diarrhea, wherein the concentration of the medicinal liquid is 1g/mL, 0.4 mL/dose, and the medicinal liquid is orally taken once a day.
The pathogenic bacteria plant is selected from the isolated and identified strong pathogenic strains, the mice are observed every 2 hours after infection, when diarrhea symptoms appear in the mice, the mice are treated by using test drugs, and the clinical symptoms and the death rate of the mice within 7 days are observed after administration.
Part of mice are about 48 hours after administration, the spirit is gradually improved, diarrhea symptoms are relieved, the diarrhea symptoms are basically avoided at the 4 th to 5 th days after administration, other mice basically have no obvious abnormal clinical symptoms except part of mice die, and analysis of test results shows that the cure rate of the mice in an antibiotic treatment group only reaches 60%; in the treatment group of the compound preparation (liquid type) of the halostachys sieboldii for treating animal diarrhea, the curative effect is the same as that of an antibiotic group, no surviving mice are seen in an infection control group, and no morbidity phenomenon exists in a negative control group.
Table 8 experiments on treatment of mice with veterinary formulations (liquid) for diarrhea
Table 9 statistics of cure rate of veterinary formulation (liquid) for diarrhea to mice
Experimental example 4
Treatment test of diarrhea-treating veterinary preparation (liquid type) on rabbit
30 rabbits were arbitrarily divided into 5 groups of 6 animals each, namely, a healthy control group (without any treatment), a compound high-dose group (1.5 g/mL, intraperitoneal injection, 1 mL/kg), a compound medium-dose group (1 g/mL, intraperitoneal injection, 1 mL/kg), a compound low-dose group (0.5 g/mL, intraperitoneal injection, 1 mL/kg), and a positive infection group (infected with E.coli only, without treatment), and the treatment with the Chinese medicine was performed 2 times daily for 6 consecutive days.
Inoculating pathogenic escherichia coli in an LB liquid culture medium, culturing for 18-24 hours, preparing bacterial suspension, weighing rabbits by using a 0.5 Mitsubishi turbidimetric tube, injecting 0.1mL/kg of escherichia coli with the concentration of 0.5 barley into the abdominal cavity, and orally taking 2mL/kg of 0.5 escherichia coli until diarrhea symptoms appear.
The rabbits with diarrhea are administrated for one treatment course (6 days), and the conditions of feeding, drinking, activity, spirit, excrement and the like of the rabbits are observed and recorded until diarrhea symptoms of the rabbits disappear, the disease is cured or the rabbits die, all the rabbits in healthy control groups die under the condition of normal feeding, abdomen bulge occurs in dissection, ascites occurs, and the cecum part bulge is serious.
Table 10 experiment for treating diarrhea with veterinary preparation (liquid type) for rabbit
Experimental example 5
Treatment effect observation of veterinary preparation (liquid) for treating diarrhea on lamb diarrhea
Table 11 animal preparation for diarrhea (liquid) treatment experiments on lambs
| Group of | Number of lambs (Only) | Improvement number of 3 days | Improvement number of 6 days | Number of invalidity | Number of deaths | Effective rate of |
| Compound treatment group of halostachys sieboldii | 6 | 6 | 6 | 0 | 0 | 100％ |
| Gentamicin plus streptomycin treatment group | 6 | 6 | 0 | 0 | 0 | 100％ |
1. In a sheep farm in Yecheng county in karis area of Xinjiang, 6 lambs with diarrhea on the same day are randomly divided into 2 groups, and the first 3 lambs with diarrhea are treated by using a veterinary preparation (liquid type) for treating diarrhea (0.5 mL/kg, intramuscular injection, 2 times a day and 7 continuous days); the second group of diarrhea lambs was treated with gentamicin sulphate injection (10 mg/kg, 2 times daily for 3 days) +streptomycin sulphate (10 mg/kg, 2 times daily for 3 days).
The test result shows that the compound preparation (liquid) of the antibiotic and the livestock salt spike wood has good curative effect on diarrhea lambs, the diarrhea symptom of the lambs is effectively controlled, and the diarrhea treatment veterinary preparation (liquid) can be used for treating lamb diarrhea.
2. In a sheep farm in Zhengle county in Xinjiang Hetian, 7 lambs with diarrhea occurring on the same day are randomly divided into 2 groups, and the first 4 diarrhea lambs are treated by using a veterinary preparation (tablet) for treating diarrhea (each tablet is equivalent to 1g of a primary drug, the dosage of the lambs is 1.6g/kg, and the preparation is orally taken, 2 times a day and 7 days after the use); the second group of diarrhea lambs is treated with ofloxacin injection (3-5 mg/kg, intramuscular injection 2 times a day, 3 days for continuous use) +poplar flower oral liquid (1 g per lml equivalent to the primary drug, 10-20 ml for sheep and pigs, 2 times a day, 3 days for continuous use).
Table 12 treatment experiments of veterinary formulations (tablets) for diarrhea on lambs
Clinical experiments prove that the veterinary preparation (tablet) for treating diarrhea has good treatment effect on lamb diarrhea, and can be popularized and used.
Table 13 treatment experiments of veterinary formulations (tablets) for diarrhea on lambs
| Group of | Number of lambs (Only) | Improvement number of 3 days | Improvement number of 6 days | Number of invalidity | Number of deaths | Effective rate of |
| Control group | 4 | 0 | 0 | 4 | 2 | 0 |
| Compound treatment group of halostachys sieboldii | 6 | 3 | 2 | 0 | 0 | 83％ |
| Qingdao treatment group | 6 | 3 | 2 | 0 | 0 | 83％ |
3. In some sheep farm in Kong-Ping county in Arctos area of Xinjiang, selecting 16 lambs with diarrhea symptoms in one week, dividing the lambs into three groups, and taking 4 lambs with diarrhea without medicine; the compound salt spike wood treatment group has 6 diarrhea lambs, and the compound salt spike wood preparation (tablet) for animals with diarrhea is orally taken, and is used for treating the diarrhea of animals, 2 tablets at a time and 2 times a day for 6 days; in the antibiotic treatment group, 6 lambs with diarrhea are injected with gentamicin sulfate injection, 24mg/kg, 2 times a day for 6 days.
From test results, after the diarrhea lamb takes the veterinary preparation (tablet) for treating diarrhea, diarrhea conditions are obviously improved, after the diarrhea lamb is taken, indexes such as body temperature, pulse and breath of the diarrhea lamb are normal, appetite is recovered, the weight gain rate of the lamb group treated by gentamicin is lower than that of the lamb group treated by the veterinary compound preparation (tablet) for treating animal diarrhea, and the animal preparation (tablet) for treating diarrhea can promote the growth of the lamb, and has no obvious difference from the treatment effect of antibiotic injection.
Experimental example 6
Treatment effect observation of veterinary preparation (tablet) for treating diarrhea on calf diarrhea
In a Holstein dairy farm of Xinjiang Al Su Deou, 40 calves with diarrhea in the sucking period are selected, and a salt spike wood compound preparation (tablet) for treating animal diarrhea is adopted for treatment, wherein the weight of the calves is about 30-50kg, and the consumption of the calves is as follows: 1 tablet/8 kg, is orally taken 2 times a day, takes 5 days as a treatment course, and has the dosage of about 4 tablets at a time.
Table 12 therapeutic effect unit of veterinary formulation (tablet) for treating diarrhea on calves: head
| Therapeutic effects | Deterioration of | Unchanged | Improvement of | Rehabilitation | Death of |
| First course of treatment | 4 | 14 | 21 | 1 | 0 |
| Second course of treatment | 3 | 9 | 19 | 7 | 2 |
| The third course of treatment | 2 | 7 | 12 | 16 | 2 |
| Fourth course of treatment | 0 | 2 | 6 | 28 | 0 |
From the clinical application, 28 calves with diarrhea are cured in four treatment periods, the cure rate is 70%, the death rate is 4, the death rate is 10%, the effective rate is 34, the effective rate is 85%, the ineffective rate is 6, the ineffective rate is 15%, and the research results show that the causes of the calf diarrhea are mainly escherichia coli, rotavirus, coronavirus and viral diarrhea, and cryptosporidium are mostly mixed infection, and the veterinary preparation (tablet) for treating diarrhea is effective for treating calf diarrhea.
Experimental example 7
Treatment effect observation of veterinary preparation (tablet) for treating diarrhea on piglet diarrhea
1. In a pig farm in Alar in the region of Achausu, 50 piglets with diarrhea disease of 7-14 days old are selected and divided into 4 groups, a control group and 5 piglets, and only antibiotics (gentamicin) are used; the compound salt spike wood treatment group comprises 15 animals, and the compound salt spike wood preparation (liquid type and tablet type) for treating animal diarrhea and the dosage of the veterinary preparation (tablet) for treating diarrhea are used: orally taken, 1 tablet/2 kg body weight, 3 times a day; dosage of liquid dosage form: intramuscular injection, 2 mL/time, 2 times a day; day 7 is a treatment cycle.
Table 13 veterinary formulation (tablet) for treating diarrhea grouping and administration of piglets
| Group of | Diarrhea pigling number | Administration of drugs |
| Compound tablet type treatment group of halostachys sieboldii | 15 | 2-3 tablets of salt spike wood compound tablet preparation (oral administration) |
| Compound liquid preparation type treatment group of halostachys sieboldii | 15 | 3-5mL salt spike wood compound liquid preparation (intramuscular injection) |
| Antibiotic treatment group | 15 | Normal gentamicin treatment regimen |
| Control group | 5 | Without any medication |
Table 14 results of treating diarrhea with veterinary formulation for diarrhea piglets
As can be seen from the data in table 14, the cure rate of the test group (100%) of the compound salt spike wood preparation for animals treating diarrhea in the test is significantly higher than that of the test group (86.67% of the tablet preparation); the cure rate (average cure rate 93.34%) of the compound preparation of the halostachys sieboldii for treating animal diarrhea is remarkably higher than that of an antibiotic treatment group (60%), and the cure rate difference is remarkable.
Table 15 grouping and administration of diarrhea piglets
2. In a pig farm in Akesu city in Akesu region of Xinjiang, 60 piglets suffering from diarrhea are selected and divided into 3 groups, namely a western medicine group, a traditional Chinese medicine group and a traditional Chinese medicine and western medicine group, wherein 20 piglets are respectively grouped and used in the table 15.
Surface 16 statistics of treatment effect observation test results of veterinary preparation for treating diarrhea
From the treatment results, the western medicine group is compared with the traditional Chinese medicine group, the cure rate is the same, the average administration days of the traditional Chinese medicine group are slightly reduced, compared with the curative effect of gentamicin in the western medicine group, the curative effect of the veterinary preparation (tablet) for treating diarrhea of the traditional Chinese medicine group is improved to a certain extent, but the difference is small, compared with the traditional Chinese medicine group and the traditional Chinese medicine+western medicine group, the cure rate is improved, compared with the single use of gentamicin in the western medicine group and the single use of the veterinary preparation (tablet) for treating diarrhea of the traditional Chinese medicine group, the average administration days are further reduced, and the curative effect can be enhanced when the veterinary preparation (tablet) for treating diarrhea and the gentamicin are mixed in treatment, so that the effect of faster cure is achieved.
In summary, the veterinary preparation (tablet) for treating diarrhea plays a good role in treating piglet diarrhea caused by escherichia coli, the effect is compared with traditional antibiotic medicines such as gentamicin, the curative effect is slightly improved but the difference is not obvious, and the curative effect and the average administration days develop in good directions when the veterinary preparation (tablet) and the antibiotic medicines are used simultaneously, so that the influence degree of the disease on piglets is effectively reduced, and the illness days are reduced.
Although embodiments of the present invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made therein without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
The invention and its embodiments have been described above with no limitation, and the actual construction is not limited to the embodiments of the invention as shown in the drawings. In summary, if one of ordinary skill in the art is informed by this disclosure, a structural manner and an embodiment similar to the technical solution should not be creatively devised without departing from the gist of the present invention.
Claims (10)
1. A veterinary preparation for treating diarrhea, which is characterized in that: the veterinary preparation for treating diarrhea is a tablet, and comprises the following components in percentage by weight: 40% of crude salt spike wood alcohol extract, 60% of pulsatilla chinensis and 60% of oleaster water extract.
2. A veterinary formulation for treating diarrhea according to claim 1, wherein: the veterinary preparation for treating diarrhea is a liquid preparation, and comprises the following components in percentage by weight: 40% of salt spike wood, 30% of oleaster and 30% of pulsatilla chinensis.
3. The veterinary formulation for treating diarrhea according to claim 2, wherein: the veterinary preparation for treating diarrhea is one of a tablet and a liquid.
4. A method of preparing a veterinary formulation for treating diarrhea according to claim 3, wherein: the method comprises the following steps:
(1) Preparing a crude extract of the spica gracilis: 200g of salt spike wood stem leaves are weighed, crushed, added into 1000mL of 85% ethanol solution, soaked for 12-24h, subjected to ultrasonic treatment for 30min, then subjected to suction filtration, finally subjected to vacuum concentration by using a rotary evaporator, repeatedly soaked and suction filtered for three times by each sample, and the salt spike wood soaked solutions recovered for 3 times under reduced pressure are combined and concentrated into 1g/mL of medicine concentration liquid, and stored at 4 ℃ for standby;
(2) Preparing a water extract of pulsatilla chinensis and elaeagnus angustifolia: weighing 100g of pulsatilla chinensis and fructus oleaster respectively, crushing, wrapping with 3 layers of medical gauze respectively, adding distilled water respectively for soaking for 4 hours, adding distilled water 10, 8 and 6 times of the volume of the traditional Chinese medicines respectively for decoction, continuously decocting with slow fire for 1 hour after each decoction boiling, suction filtering and preserving, finally merging the 3 times of filtrate for concentration, and preserving at 4 ℃ for later use;
(3) Preparation of compound preparation (liquid agent): uniformly mixing the crude extract of the spica, the pulsatilla chinensis and the water extract of the oleaster prepared in the step (1) and the step (2) according to a proportion to form a veterinary salt spica compound preparation for treating animal diarrhea;
(4) Preparation of compound preparation (tablet): pulverizing Salicomia Herbacea, fructus Elaeagni Angustifoliae and radix Pulsatillae, mixing at a certain proportion, adding starch, mixing, and tabletting with tablet machine, wherein each tablet is 1g of crude drug.
5. The method for preparing a veterinary preparation for treating diarrhea according to claim 4, wherein: the soaking in the step (1) should be in a light-proof environment.
6. The method for preparing a veterinary preparation for treating diarrhea according to claim 5, wherein: the final crude drug concentration in the step (2) is 1g/mL.
7. The method for preparing a veterinary preparation for treating diarrhea according to claim 6, wherein: the concentration of the liquid medicine in the step (3) is 1g/mL.
8. The method for preparing a veterinary preparation for treating diarrhea according to claim 7, wherein: the ratio of the traditional Chinese medicine powder to the starch in the step (4) is 1:1.2.
9. The method for preparing a veterinary preparation for treating diarrhea according to claim 8, wherein: the halostachys sieboldii liquid for treating animal diarrhea can be applied to: mouse dosage: 0.4 mL/dose, orally taken, 1 time a day, and continuously taken for 3d; rabbit dosage: 1mL/kg, intraperitoneal injection, 1 time a day, continuous administration of 6d and piglet dosage: intramuscular injection, 2 mL/time, 2 times a day, was continued for 6d.
10. The method for preparing a veterinary preparation for treating diarrhea according to claim 9, wherein: the veterinary halostachys sieboldii tablet for treating animal diarrhea can be applied to: lamb consumption: 1.6g/kg, or 2 tablets at a time, orally taken 2-3 times a day, and continuously taken for 6d; calf dosage: 4 tablets each time are orally taken for 2-3 times a day, and the medicine is continuously taken for 6 days; the dosage of piglets is as follows: 2-4 tablets each time are orally taken, 2-3 times a day, and the medicine is continuously taken for 6 days.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311267475.2A CN117244002A (en) | 2023-09-28 | 2023-09-28 | Veterinary preparation for treating diarrhea |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311267475.2A CN117244002A (en) | 2023-09-28 | 2023-09-28 | Veterinary preparation for treating diarrhea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117244002A true CN117244002A (en) | 2023-12-19 |
Family
ID=89128982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311267475.2A Pending CN117244002A (en) | 2023-09-28 | 2023-09-28 | Veterinary preparation for treating diarrhea |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117244002A (en) |
-
2023
- 2023-09-28 CN CN202311267475.2A patent/CN117244002A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101664421A (en) | Traditional Chinese biological preparation for preventing and treating livestock diarrhea and preparation method thereof | |
| CN106728000A (en) | A kind of macleaya cordata baikal skullcap root composition and its application for veterinary drug or medicated feed additive | |
| CN110787247B (en) | Traditional Chinese medicine microecological preparation for preventing and treating livestock and poultry diarrhea and preparation method thereof | |
| MX2011006273A (en) | Feed for preventing and/or treating diseases due to clostridium sp. bacteria in livestock, and anti-clostridium agent. | |
| CN105287790B (en) | A kind of fevervine extract and its application | |
| CN103202409B (en) | Special feed additive for grass carp | |
| CN101209330A (en) | Compound Chinese medicinal granule with heat-clearing and detoxication, worm-expelling and liver-protecting efficacy | |
| CN104887843A (en) | Chinese medicinal composition for prevention and treatment of fish gill rot disease and preparation method thereof | |
| CN106039138B (en) | Lactic acid bacteria traditional Chinese medicine fermentation antiviral preparation for aquaculture | |
| CN102805772B (en) | Application of coptis chinensis, amur cork-tree bark, Chinese rhubarb and skullcap dysentery inhibiting particles to preparation of medicines for treating intestinal diseases of poultry, and medicinal composition formed by compounding particles | |
| CN117244002A (en) | Veterinary preparation for treating diarrhea | |
| CN102266521B (en) | Traditional Chinese medicine preparation for treating bacterial enteritis of sea fish, and preparation method thereof | |
| CN104758347B (en) | Traditional Chinese medicine oral liquid for treating pullorum disease and preparation method thereof | |
| CN111632094B (en) | Application of composition in preventing or treating diseases caused by escherichia coli of broiler chicken | |
| CN104721337A (en) | Traditional Chinese medicine composition, preparation method and application thereof | |
| CN109432287B (en) | Traditional Chinese medicine oral liquid for preventing and treating excessive heat syndrome of poultry qi system and preparation method thereof | |
| CN106109667A (en) | A kind of Chinese medicine composition improving enteric flora disturbance and its production and use | |
| CN107789394B (en) | Composition for treating livestock and poultry diarrhea | |
| CN115607614B (en) | Traditional Chinese medicine composition for treating colibacillosis of livestock and poultry and preparation method thereof | |
| CN107714838A (en) | A kind of Chinese medicine composition for preventing and treating diarrhea of weaned piglets and its application | |
| CN115919951B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN111281922B (en) | Compound traditional Chinese veterinary medicine oral preparation for treating diarrhea of pigs and poultry and preparation method thereof | |
| CN110150486A (en) | A kind of feed addictive for preventing and treating the intestines problems such as milking sow constipation diarrhea | |
| CN110141590B (en) | Kosteletzkya virginica traditional Chinese medicine composite composition for preventing and treating chicken coccidiosis and application thereof | |
| CN111617203B (en) | Application of composition in preventing or treating diseases caused by infection of escherichia coli |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |